What are the guidelines for using antihistamines, such as diphenhydramine (Benadryl) or loratadine (Claritin), in pediatric patients with allergic reactions or conditions like atopic dermatitis, considering age, weight, and medical history?

Antihistamine Use in Pediatric Patients

Direct Recommendation

Antihistamines should NOT be routinely used in children with atopic dermatitis, as there is insufficient evidence for efficacy; however, second-generation antihistamines (cetirizine, loratadine) are the preferred agents for allergic rhinitis and urticaria in children ≥6 months, while first-generation antihistamines like diphenhydramine should be avoided in children under 6 years except for anaphylaxis. 1, 2

---

Age-Specific Safety Guidelines

Children Under 6 Months

• Antihistamines are contraindicated for routine use in infants under 6 months of age 2
• Chlorpheniramine should NOT be used in this age group 2
• Allergen avoidance and supportive care should be the primary management strategy 2

Children 6 Months to Under 2 Years

• Second-generation antihistamines are preferred: cetirizine, desloratadine, fexofenadine, levocetirizine, and loratadine have well-tolerated safety profiles 1, 3
• Cetirizine is the preferred antihistamine for infants ≥6 months, with safety profile similar to placebo 2
• Dosing for cetirizine in infants 6-11 months: 0.25 mg/kg twice daily (approximately 2.5 mg twice daily for a 10 kg infant) 3
• First-generation antihistamines (diphenhydramine, chlorpheniramine) should be avoided due to 69 fatalities reported between 1969-2006 in children ≤6 years, with 41 deaths in children under 2 years 2, 3

Children 2 to Under 6 Years

• FDA-approved dosing for loratadine: 1 teaspoonful (5 mg) daily; do not exceed 1 teaspoonful in 24 hours 4
• FDA-approved dosing for cetirizine: 2.5 mg once or twice daily 3
• Intranasal antihistamines (azelastine, olopatadine) are NOT approved for children under 6 years 3

Children 6 to Under 12 Years

• Diphenhydramine dosing per FDA label: 10 mL (25 mg) every 4-6 hours, maximum 6 doses in 24 hours 5
• Loratadine dosing per FDA label: 2 teaspoonfuls (10 mg) daily 4
• Important caveat: Sedating antihistamines may negatively affect school performance, warranting careful attention to dosage and timing 1

Children 12 Years and Older

• Diphenhydramine dosing: 10-20 mL (25-50 mg) every 4-6 hours, maximum 6 doses in 24 hours 5
• Adult dosing guidelines generally apply 5

---

Condition-Specific Recommendations

Atopic Dermatitis

Antihistamines are NOT recommended for routine management of atopic dermatitis. 1

• Evidence from 16 randomized controlled trials shows non-sedating antihistamines are ineffectual in AD management 1
• The Early Treatment of the Atopic Child (ETAC) trial demonstrated cetirizine showed no statistically significant improvement in overall AD control in infants 12-24 months 1
• Limited exception: Short-term, intermittent use of sedating antihistamines may be beneficial for sleep loss secondary to itch, but should NOT substitute for topical therapies 1
• A dose-ranging study showed 4-fold standard cetirizine dose (40mg daily) was necessary for significant improvement in adults, attributed to sedating effects rather than antihistamine properties 1
• Topical corticosteroids remain first-line treatment for AD, not antihistamines 6

Allergic Rhinitis

Intranasal corticosteroids are the most effective medications for allergic rhinitis in children, superior to antihistamines. 1, 3

• Second-generation antihistamines (cetirizine, loratadine, desloratadine, fexofenadine, levocetirizine) are well-tolerated alternatives with good safety profiles 1, 3
• Treatment algorithm for children under 2 years: Start with intranasal corticosteroids as first-line, followed by second-generation antihistamines as second-line, with saline irrigation as adjunctive therapy 3
• Intranasal corticosteroids control all four major symptoms (sneezing, itching, rhinorrhea, nasal congestion) more effectively than antihistamines 3
• When given in recommended doses, intranasal corticosteroids are not associated with clinically significant systemic side effects 1

Chronic Cough

Antihistamines have minimal to no efficacy in relieving cough in children. 1

• A systematic review showed antihistamine and decongestant combinations were no more effective than placebo in reducing acute cough in children 1
• A recent RCT demonstrated diphenhydramine and dextromethorphan were no different than placebo in reducing nocturnal cough or sleep disturbance 1
• Meta-analysis showed antihistamine monotherapy or combinations with decongestants were ineffective in children ≤15 years for common cold symptoms 1

Anaphylaxis

Diphenhydramine is indicated as adjunctive treatment in anaphylaxis, but epinephrine remains the primary treatment. 7

• Chlorpheniramine dose for anaphylaxis in infants 6 months to 1 year: 250 µg/kg (2.5 mg IM or IV slowly) 2
• This is the ONLY indication for first-generation antihistamines in young children 2, 7

---

Critical Safety Concerns and Adverse Effects

First-Generation Antihistamines (Diphenhydramine, Chlorpheniramine)

• Between 1969-2006,69 fatalities associated with antihistamines in children ≤6 years, with 41 deaths in children under 2 years 2, 3
• FDA advisory committees recommended against OTC cough/cold medications containing first-generation antihistamines in children under 6 years 2
• Common adverse effects include undesired sedation (even with "non-sedating" formulations), anticholinergic symptoms (dry mouth, blurred vision, tachycardia) 1
• Impair CNS function far more commonly than generally realized 7
• Convulsions have been reported with chlorpheniramine, requiring special caution in patients with epilepsy 2
• If antihistamine toxicity is suspected, obtain EKG to assess for dysrhythmia 1

Second-Generation Antihistamines

• Generally well-tolerated with excellent safety profiles in children over 6 months 1, 3
• Possible sedation may occur with higher than usual doses of cetirizine and loratadine 3
• Cetirizine requires 50% dose reduction in moderate renal impairment and should be avoided in severe renal impairment 2
• Levocetirizine has significant association with epilepsy (ROR 6.57) based on VigiBase data 8

---

Common Pitfalls to Avoid

1. Do not use antihistamines as primary treatment for atopic dermatitis – they do not improve disease control and should not substitute for topical corticosteroids 1, 6

2. Do not combine antihistamines with other sedating medications without considering additive CNS depression effects 2

3. Do not use first-generation antihistamines in children under 6 years except for anaphylaxis, due to documented fatalities and safety concerns 2, 3

4. Do not prescribe intranasal antihistamines (azelastine, olopatadine) in children under 6 years – they lack FDA approval for this age group 3

5. Do not use diphenhydramine in children under 6 years per FDA labeling 5

6. Do not exceed recommended doses – higher doses increase sedation risk without improving antihistamine efficacy 1, 3

7. Do not use antihistamines for chronic cough – evidence shows no benefit over placebo 1

8. Avoid sedating antihistamines in school-age children during school hours due to negative effects on academic performance 1

---

Special Populations

Renal Impairment

• Cetirizine requires dose adjustment: 50% reduction in moderate renal impairment; avoid in severe renal impairment 2
• Consult product information for other antihistamines 1

Hepatic Impairment

• Loratadine: Consult physician before use in consumers with liver disease 4
• Review individual drug profiles for specific recommendations 1

Infants with High-Risk Allergic Conditions

• Second-generation antihistamines may have beneficial effects in children with mild asthma 7
• Role in delaying or preventing asthma development in high-risk infants is under investigation 7